BIONTECH AG based in Mainz, DE has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2020-12-10 ✅ Patent 11,795,218 granted on 2023-10-24

US20200385460A1

Chemistry; metallurgy

Diagnosis and therapy of cancer involving cancer stem cells

#2 | 2019-02-28

US20190062762A1

Chemistry; metallurgy

Modification of RNA, Producing an Increased Transcript Stability and Translation Efficiency

#3 | 2019-02-21 ✅ Patent 10,717,780 granted on 2020-07-21

US20190055311A1

Chemistry; metallurgy

Agents for treatment of claudin expressing cancer diseases

#4 | 2018-10-11 ✅ Patent 10,980,875 granted on 2021-04-20

US20180289797A1

Human necessities

Cytotoxic immunostimulating particles and uses thereof

#5 | 2018-06-28 ✅ Patent 11,298,426 granted on 2022-04-12

US20180177885A1

Human necessities

Recombinant vaccines and use thereof

#6 | 2018-06-21 ✅ Patent 10,724,103 granted on 2020-07-28

US20180169236A1

Human necessities

Identification of surface associated antigen FLJ31461 for tumor diagnosis and therapy

#7 | 2018-02-08 ✅ Patent 10,370,433 granted on 2019-08-06

US20180037632A1

Chemistry; metallurgy

Compositions and methods for diagnosis and treatment of cancer

#8 | 2017-11-02 ✅ Patent 10,253,373 granted on 2019-04-09

US20170314078A1

Chemistry; metallurgy

Identification of tumor-associated markers for diagnosis and therapy

#9 | 2017-09-21 ✅ Patent 10,172,960 granted on 2019-01-08

US20170266301A1

Human necessities

Particles comprising single stranded RNA and double stranded RNA for immunomodulation

#10 | 2017-05-18 ✅ Patent 10,626,400 granted on 2020-04-21

US20170136129A1

Human necessities

Stabilised formulations of RNA

#11 | 2017-02-23 ✅ Patent 10,302,647 granted on 2019-05-28

US20170052187A1

Physics

Identification of surface-associated antigens for tumor diagnosis and therapy

#12 | 2017-01-12 ✅ Patent 10,106,800 granted on 2018-10-23

US20170009244A1

Chemistry; metallurgy

Modification of RNA, producing an increased transcript stability and translation efficiency

#13 | 2016-11-03 ✅ Patent 9,730,976 granted on 2017-08-15

US20160317605A1

Human necessities

Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers

#14 | 2016-09-22 ✅ Patent 10,093,736 granted on 2018-10-09

US20160272711A1

Chemistry; metallurgy

Agents for treatment of claudin expressing cancer diseases

#15 | 2016-07-07 ✅ Patent 9,910,043 granted on 2018-03-06

US20160195539A1

Physics

Identification of tumor-associated cell surface antigens for diagnosis and therapy

#16 | 2016-05-05 ✅ Patent 11,222,711 granted on 2022-01-11

US20160125129A1

Physics

Predicting immunogenicity of T cell epitopes

#17 | 2015-12-31 ✅ Patent 9,267,177 granted on 2016-02-23

US20150376718A1

Chemistry; metallurgy

Identification of tumor-associated cell surface antigens for diagnosis and therapy

#18 | 2015-06-04 ✅ Patent 9,944,708 granted on 2018-04-17

US20150152186A1

Chemistry; metallurgy

Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZe (antibody-mediated apoptosis inducing cytokines)

#19 | 2015-06-04 ✅ Patent 9,617,321 granted on 2017-04-11

US20150152154A1

Chemistry; metallurgy

Tumor vaccination involving a humoral immune response against self-proteins

#20 | 2015-04-30 ✅ Patent 9,321,808 granted on 2016-04-26

US20150119342A1

Chemistry; metallurgy

Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers

#21 | 2015-03-26 ✅ Patent 10,485,884 granted on 2019-11-26

US20150086612A1

Human necessities

RNA formulation for immunotherapy

#22 | 2014-11-27 ✅ Patent 9,636,414 granted on 2017-05-02

US20140348924A1

Human necessities

Particles comprising single stranded RNA and double stranded RNA for immunomodulation

#23 | 2014-05-15

US20140134201A1

Human necessities

RECOMBINANT VACCINES AND USE THEREOF

#24 | 2014-05-01 ✅ Patent 9,533,043 granted on 2017-01-03

US20140120085A1

Chemistry; metallurgy

Identification of surface-associated antigens for tumor diagnosis and therapy

#25 | 2014-01-30

US20140030808A1

Chemistry; metallurgy

Method for Cellular RNA Expression

#26 | 2014-01-16 ✅ Patent 9,194,004 granted on 2015-11-24

US20140017679A1

Chemistry; metallurgy

Identification of surface-associated antigens for tumor diagnosis and therapy

#27 | 2013-10-17 ✅ Patent 9,586,997 granted on 2017-03-07

US20130273647A1

Chemistry; metallurgy

Antigen-specific T cell receptors and T cell epitopes

#28 | 2013-09-19 ✅ Patent 9,637,794 granted on 2017-05-02

US20130243796A1

Chemistry; metallurgy

Genetic products differentially expressed in tumors and use thereof

#29 | 2013-08-29 ✅ Patent 9,061,007 granted on 2015-06-23

US20130224214A1

Human necessities

Compositions and methods for therapy and diagnosis of cancer and cancer metastasis

#30 | 2013-01-10 ✅ Patent 8,637,006 granted on 2014-01-28

US20130011426A1

Human necessities

Recombinant vaccines and use thereof

#31 | 2012-08-02 ✅ Patent 9,295,717 granted on 2016-03-29

US20120195917A1

Human necessities

Vaccine composition comprising 5′-cap modified RNA

#32 | 2011-12-22 ✅ Patent 9,486,519 granted on 2016-11-08

US20110311584A1

Human necessities

Use of FLT3 ligand for enhancing immune responses in RNA immunization

#33 | 2011-05-05 ✅ Patent 9,175,088 granted on 2015-11-03

US20110104147A1

Chemistry; metallurgy

Identification of tumor-associated markers for diagnosing or monitoring ovarian cancer

#34 | 2010-10-21

US20100267610A1

Chemistry; metallurgy

Polypeptide comprising a knottin protein moiety

#35 | 2010-05-27 ✅ Patent 9,476,055 granted on 2016-10-25

US20100129877A1

Chemistry; metallurgy

Modification of RNA, producing an increased transcript stability and translation efficiency

#36 | 2010-05-06 ✅ Patent 8,178,653 granted on 2012-05-15

US20100111993A1

Human necessities

Recombinant vaccines and use thereof

Also check out BioNTech AG's (Mainz, Germany) applicant profile with 33 patent applications submitted.

AssigneeID:

42667 ⎘